ALVR Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 112709 min ago

@ $0.677

Wydano: 14 vas. 2024 @ 22:54

Zwrot: 19.08%

Poprzedni sygnał: vas. 13 - 20:31

Poprzedni sygnał: Sprzedaż

Zwrot: 0.83 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	141 181
Średni wolumen	594 178
Kapitalizacja rynkowa	92.68M
EPS	$0 ( 2024-03-20 )
Następna data zysków	( $0 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.440
ATR14	$0.00300 (0.37%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Hagen Brett R	Sell	473	Common Stock
2024-04-22	Hagen Brett R	Sell	480	Common Stock
2024-04-19	Miller Edward	Sell	626	Common Stock
2024-04-22	Miller Edward	Sell	757	Common Stock
2024-04-19	Brainard Diana	Sell	9 601	Common Stock

INSIDER POWER
83.65
Last 98 transactions
Buy: 5 809 216 \| Sell: 427 568

Wolumen Korelacja

Długi: 0.13 (neutral)

Krótki: -0.14 (neutral)

Signal:(48.309) Neutral

AlloVir, Inc. Korelacja

10 Najbardziej pozytywne korelacje
BCLI	0.953
CVAC	0.952
CRNC	0.951
RSLS	0.949
PYPD	0.948
LYT	0.947
IKT	0.944
TNYA	0.944
RANI	0.943
SONN	0.942

10 Najbardziej negatywne korelacje
EBSB	-0.952
HERA	-0.95
ISEE	-0.949
FXCO	-0.946
MTRX	-0.944
GXII	-0.943
FTPA	-0.943
NOVV	-0.943
TBSA	-0.942
HERAU	-0.94

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

AlloVir, Inc. Korelacja - Waluta/Towar

0.54
( weak )

0.58
( weak )

0.00
( neutral )

-0.60
( weak negative )

AlloVir, Inc. Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-398 000 (0.00 %)
EPS:	$-1.830

FY	2023
Przychody:	$0
Zysk brutto:	$-398 000 (0.00 %)
EPS:	$-1.830

FY	2022
Przychody:	$0
Zysk brutto:	$-2.57M (0.00 %)
EPS:	$-2.20

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-6.39

Financial Reports:

No articles found.

AlloVir, Inc.

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.